the aid library

LIST OPTIONS

Filter

459

Download (386)

View PDF (661)

Nchoputa Gbasara Ahuike Umunwanyi, Umunwoke na Umuaka: Mpaghara Owuwa Anyanwu (South East)

National Population Commission (NPC), Abuja; The DHS Program, Rockville (2014) C1

Download (581)

View PDF (987)

Naijiria: NCHOPUTA GBASARA AHUIKE UMUNWANYI, UMUNWOKE NA UMUAKA

The DHS Program, Rockville (2014) C1

Download (1038)

View PDF (2157)

Toma y envio de muestras de heces para estudios diagnosticos de V. cholerae

Organización Mundial de la Salud OMS (2010) C_WHO

Procedimientos para la identificación de Vibrio cholerae en el laboratorio de microbiología

Download (542)

View PDF (681)

Recomendaciones para evitar la Leptospirosis

Ministerio de Salud Pública y Bienestar Social, DGVS Paraguay, et al. (2017) C1

Download (396)

View PDF (508)

Manual - Para el diagnóstico bacteriológico de la Tuberculosis (Parte 1 Baciloscopia)

M. D. S. de Latini; L. Barrera Oranizatión Panamerica de la Salud; Organización Mundial de la Salud; USAID America (2008) C_WHO

Normas y Guía técnica

Download (97)

View PDF (115)

Procedimiento para el manejo de cadáveres de casos de COVID-19 - Documento técnico

Centro de Coordinación de Alertas y Emergencias Sanitarias Ministerio de sanidad - España (2020) C1

External Link

How do vaccines work?

World Health Organization WHO (2021) C_WHO

This article is part four in a series of explainers on vaccine development and distribution Available in different languages

External Link

How are vaccines developed?

World Health Organization WHO (2021) C_WHO

This article is part two in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. This article focuses on the ingredients in a vaccine and the three clinical trial phases. Part three outlines the nex... more

Pertussis Vaccine-Preventable Diseases Surveillance Standards

World Health Organization WHO (2018) C_WHO

The objectives of pertussis surveillance are to:hmonitor disease burden and the impact of the pertussis vaccination programme, with a special focus on understanding the morbidity and mortality in children < 5 years of agehgenerate data to inform vaccine schedule and delivery strategy decisions to op... more

Lineamientos técnicos para el usode la rueba de Lipoarabinomanano (LAM) como apoya diagnostico en patientes con VIH y sospecha de tuberculosis

Alabí Montoya, F.J.; C.G. Alvarenga Cardoza, K.M. Díaz de Naves Ministerio de Salud El Salvador (2021) C1

LAM test as a diagnostic aid in patients with HIV and suspected tuberculosis: technical guidelines

Download (162)

View PDF (185)

Estudio sobre los efectos en la salud mental de niñas, niños y adolescentes por COVID-19

UN Children's Fund UNICEF (2021) C_UNICEF

La presente investigación se realizó con el objetivo de generar información que permita conocer los efectos que la pandemia por COVID-19 producen sobre el estado de salud mental y cambios en el comportamiento de niñas, niños y adolescentes, y presentar recomendaciones que orienten las acciones ... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Cum să faci ceea ce contează în perioade stresante: Un ghid ilustrat

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

Cum să faci ceea ce contează în perioade stresante este un ghid al OMS de gestionare a stresului, pentru a face faţă mai ușor greutăţilor. Acest ghid ilustrat vine în sprijinul implementării recomandărilor OMS pentru gestionarea stresului.